AAAAAA

   
Results: 1-11 |
Results: 11
First-line, single-agent Herceptin (R) (trastuzumab) in metastatic breast cancer: a preliminary report
Authors: Vogel, C Cobleigh, MA Tripathy, D Gutheil, JC Harris, LN Fehrenbacher, L Slamon, DJ Murphy, M Novotny, WF Burchmore, M Shak, S Stewart, SJ
Citation: C. Vogel et al., First-line, single-agent Herceptin (R) (trastuzumab) in metastatic breast cancer: a preliminary report, EUR J CANC, 37, 2001, pp. S25-S29
Pivotal study of iodine I 131 Tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas
Authors: Kaminski, MS Zelenetz, AD Press, OW Saleh, M Leonard, J Fehrenbacher, L Lister, TA Stagg, RJ Tidmarsh, GF Kroll, S Wahl, RL Knox, SJ Vose, JM
Citation: Ms. Kaminski et al., Pivotal study of iodine I 131 Tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas, J CL ONCOL, 19(19), 2001, pp. 3918-3928
First-line Herceptin (R) monotherapy in metastatic breast cancer
Authors: Vogel, CL Cobleigh, MA Tripathy, D Gutheil, JC Harris, LN Fehrenbacher, L Slamon, DJ Murphy, M Novotny, WF Burchmore, M Shak, S Stewart, SJ
Citation: Cl. Vogel et al., First-line Herceptin (R) monotherapy in metastatic breast cancer, ONCOL-BASEL, 61, 2001, pp. 37-42
Cost of care for patients in cancer clinical trials
Authors: Fireman, BH Fehrenbacher, L Gruskin, EP Ray, GT
Citation: Bh. Fireman et al., Cost of care for patients in cancer clinical trials, J NAT CANC, 92(2), 2000, pp. 136-142
Patient costs on clinical trials - Response
Authors: Fireman, B Fehrenbacher, L Ray, GT
Citation: B. Fireman et al., Patient costs on clinical trials - Response, J NAT CANC, 92(17), 2000, pp. 1442-1443
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
Authors: Saltz, LB Cox, JV Blanke, C Rosen, LS Fehrenbacher, L Moore, MJ Maroun, JA Ackland, SP Locker, PK Pirotta, N Elfring, GL Miller, LL
Citation: Lb. Saltz et al., Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer., N ENG J MED, 343(13), 2000, pp. 905-914
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
Authors: Cobleigh, MA Vogel, CL Tripathy, D Robert, NJ Scholl, S Fehrenbacher, L Wolter, JM Paton, V Shak, S Lieberman, G Slamon, DJ
Citation: Ma. Cobleigh et al., Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease, J CL ONCOL, 17(9), 1999, pp. 2639-2648
Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-25
Authors: Fisher, B Anderson, S DeCillis, A Dimitrov, N Atkins, JN Fehrenbacher, L Henry, PH Romond, EH Lanier, KS Davila, E Kardinal, CG Laufman, L Pierce, HI Abramson, N Keller, AM Hamm, JT Wickerham, DL Begovic, M Tan-Chiu, E Tian, W Wolmark, N
Citation: B. Fisher et al., Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-25, J CL ONCOL, 17(11), 1999, pp. 3374-3388
Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer
Authors: Jones, S Vogel, C Arkhipov, A Fehrenbacher, L Eisenberg, P Cooper, B Honig, S Polli, A Whaley, F di Salle, E Tiffany, J Consonni, A Miller, L
Citation: S. Jones et al., Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer, J CL ONCOL, 17(11), 1999, pp. 3418-3425
Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial
Authors: Fisher, B Dignam, J Wolmark, N Wickerham, DL Fisher, ER Mamounas, E Smith, R Begovic, M Dimitrov, NV Margolese, RG Kardinal, CG Kavanah, MT Fehrenbacher, L Oishi, RH
Citation: B. Fisher et al., Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial, LANCET, 353(9169), 1999, pp. 1993-2000
Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National surgical adjuvant breast and bowel project protocol C-05
Authors: Wolmark, N Bryant, J Smith, R Grem, J Allegra, C Hyams, D Atkins, J Dimitrov, N Oishi, R Prager, D Fehrenbacher, L Romond, E Colangelo, L Fisher, B
Citation: N. Wolmark et al., Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National surgical adjuvant breast and bowel project protocol C-05, J NAT CANC, 90(23), 1998, pp. 1810-1816
Risultati: 1-11 |